Wuxi Baifude Biotechnology Co., Ltd.
← Technical Notes

Technical Note

Feline chronic enteropathy: a raised dysbiosis index marks the more damaged gut, not a target to lower

The faecal dysbiosis index (DI) has moved from research into routine feline practice, and it is starting to appear in pet-product dossiers as an outcome: "reduced the dysbiosis index." A cross-sectional study published this week in the Journal of Feline Medicine and Surgery compared 49 healthy cats with 71 cats with chronic enteropathy (FCE). Cats with FCE differed from healthy cats in faecal microbiome and metabolome, and the subgroup with a raised DI showed stronger signals of mucosal damage, malabsorption and lost microbial function, along with lower serum cobalamin. That supports the DI as a way to stratify sick cats. It does not support treating a lower DI as a benefit in itself, and that distinction is what this note is about.

Published 19 November 2026 · 7 min read

What the study did

Design

Retrospective cross-sectional study: 49 healthy cats and 71 cats with FCE, the latter split by DI into raised (DI > 0) and normal (DI < 0).

  • Microbiome: faecal shotgun metagenomics plus the qPCR-based DI.
  • Metabolome: targeted mass spectrometry of faecal long-chain fatty acids, sterols, bile acids and carbohydrates.
  • Multivariate analyses adjusted for age.

Result

  • Overall: metabolomic, microbial and functional-gene profiles differed between FCE and healthy cats (median R² 0.16-0.19), with larger shifts in the raised-DI group.
  • Mucosal damage markers: faecal cholesterol, nervonic acid and arachidonic acid were higher in FCE and correlated with DI (r = 0.33, 0.41, 0.44).
  • Malabsorption and microbial function: higher faecal glucose and a higher primary bile acid fraction appeared only in the raised-DI group.
  • Cobalamin: significantly lower in raised-DI than in normal-DI cats with FCE.

The authors conclude that FCE is heterogeneous, and that raised-DI cats show more severe functional changes.

What the index is

The feline DI was established in 2022 by the Gastrointestinal Laboratory at Texas A&M University, the group the senior author of this paper also belongs to. It combines qPCR abundances of total bacteria and seven taxa (Bacteroides, Bifidobacterium, Clostridium hiranonis, Escherichia coli, Faecalibacterium, Streptococcus, Turicibacter) into a single score. In the development study, a cut-off of 0 separated FCE from healthy microbiota with 77% sensitivity and 96% specificity; 52 of 68 FCE cats scored above 0. A normal DI does not exclude FCE, and a raised DI describes the microbiota, not the diagnosis.

What it does and does not establish

Supportable: FCE cats differ measurably from healthy cats; within FCE, a raised DI marks cats with heavier damage, malabsorption and functional loss, including lower cobalamin; FCE should not be treated as one condition.

Needs a discount:

  • Cross-sectional and retrospective. Dysbiosis may worsen the damage, a damaged gut may drive dysbiosis, or disease activity may drive both. The design cannot separate these.
  • Moderate effect sizes. Disease status explained 16-19% of profile variation; metabolite-DI correlations were 0.33-0.44.
  • Subgroup sizes, diets and medication history are not given in the abstract. Diet type and antibiotic exposure both shift microbiota and metabolites.

The misreading to avoid: the index as an endpoint

The tempting chain is "our ingredient lowered the DI, therefore it supports gut health." The current evidence does not carry that step. The DI tracks severity; lowering the reading is not shown to lower severity.

A concrete case from this year: a crossover trial of a non-viable Lactobacillus acidophilus postbiotic in dogs and cats found that in both healthy and chronically diarrhoeic cats the DI fell, but faecal scores did not change, and dry-matter and energy digestibility in cats fell slightly. The index moved; the clinical picture did not.

A change in DI means something only when it is reported alongside clinical outcomes: faecal score, body weight, signs, cobalamin. It is the same point we made in post-antibiotic recovery: which clock?: a compositional number returning to baseline is not the same as function returning.

Two further details matter for formulators. The rise in primary bile acids points to a specific functional gap, reduced bile acid conversion, for which C. hiranonis, one of the DI taxa, is considered the main converter in cats and dogs; that is a more testable target than "microbiome balance." And the findings come from sick cats; they do not license claims for healthy cats.

A note from an ingredient manufacturer

Baifude manufactures lactic acid bacteria, bifidobacteria, Bacillus, yeast and blended functional powders, including ingredients used in pet food and pet supplements. This study bears directly on that business, so to be clear:

It tested no probiotic, postbiotic or pet food. It cannot support any product for feline chronic enteropathy, ours included.

We do not treat a lower dysbiosis index as an efficacy claim. Until DI change is linked to clinical outcomes, it is a reading to report alongside other measures.

What this means for brands and formulators

1. Do not claim a lower DI as a benefit

Anchor claims on clinical outcomes (faecal score, body weight, signs, cobalamin). Report DI as supporting data.

2. When a supplier shows a DI reduction, ask what the cats did

Request faecal scores, digestibility and clinical signs from the same animals. The postbiotic trial above is the case where the index fell and stool did not change.

3. Stratify FCE cats in trials

Raised-DI and normal-DI cats with FCE are likely different situations. Stratifying by DI will show more than averaging across them.

4. Target specific functions

Bile acid conversion and cobalamin status are concrete, measurable endpoints. "Balance" is not.

5. Keep healthy-cat and sick-cat evidence apart

Everyday products for healthy cats cannot borrow findings about cats with FCE.

6. State the veterinary boundary

FCE requires veterinary diagnosis and management. Food and supplement positioning should be nutritional support under that management, not a substitute for it.

If you are assessing this direction

We can help at the strain and documentation level: confirming what an organism is at species and strain level, and checking whether a cited companion-animal study measured an index, composition or clinical outcomes, with the same organism, dose and animal population. Carrier, processing tolerance and formulation feasibility for pet food can be discussed alongside. We do not use any study to support the efficacy of any product, ours or anyone else's.

Contact us

References

  1. Chen CC, Moraiti KT, Giordano MV, et al. Dysbiosis correlates with more severe changes in intestinal function in cats with chronic enteropathy. Journal of Feline Medicine and Surgery, 17 November 2026. doi:10.1177/1098612x261510648. PubMed 43041144
  2. Sung CH, Marsilio S, Chow B, et al. Dysbiosis index to evaluate the fecal microbiota in healthy cats and cats with chronic enteropathies. Journal of Feline Medicine and Surgery, 2022. PubMed 35266809
  3. Lin CY, Kerr KR, Panasevich MR, et al. Effects of a nonviable Lactobacillus acidophilus on apparent total tract nutrient digestibility, fecal characteristic, fecal fermentative end-products, and dysbiosis index in healthy and chronic diarrhea-affected dogs and cats. 2026. PubMed 42485239

This note summarises and interprets published research in order to explain what the feline dysbiosis index indicates in chronic enteropathy and how far such data can be cited. The reading of references 1-3 is based on the published abstracts; the full papers govern on detail. Reference 1 tested no probiotic, postbiotic or pet food. This note is not a claim about the efficacy or safety of any product, is not directed at any company or brand, and is not veterinary, nutritional or regulatory advice. Claim substantiation requirements differ between jurisdictions; the rules of the market concerned govern in every case. Findings apply only to the animal populations, assays and conditions described in the original sources. Cats with chronic diarrhoea, vomiting or weight loss should be seen by a veterinarian.